Clinical Trial

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

Name: An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis — clinical trial record (NCT06946199)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-18.

Status change: Not Yet Recruiting → Recruiting 2026-01-08

Trial Details

NCT Number	NCT06946199
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions	Rheumatoid Arthritis (RA)
Enrollment	28 participants
Start Date	2025-06-23
Primary Completion	2027-06 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-01-12